Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words 'Vermorken, JB' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 161 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Vermorken, JB; Poveda, A
      Untitled - Introduction

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    2. Vermorken, JB
      The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    3. Vermorken, JB
      Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG)

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    4. Wagenaar, HC; Pecorelli, S; Mangioni, C; van der Burg, MEL; Rotmensz, N; Anastasopoulou, A; Zola, P; Veenhof, CHN; Lacave, AJ; Neijt, JP; van Oosterom, AT; Einhorn, N; Vermorken, JB
      Phase II study of mitomycin-C and cisplatin in disseminated, squamous cellcarcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study

      EUROPEAN JOURNAL OF CANCER
    5. Duffaud, F; van der Burg, MEL; Namer, M; Vergote, I; Willemse, PHB; Huinink, WT; Guastalla, JP; Nooij, MA; Kerbrat, P; Piccart, M; Tumolo, S; Favalli, G; van der Vange, N; Lacave, AJ; Wils, J; Splinter, TAW; Einhorn, N; Roozendaal, KJ; Rosso, R; Vermorken, JB
      D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTCgynaecological cancer co-operative group study

      ANTI-CANCER DRUGS
    6. Piccart, MJ; Lamb, H; Vermorken, JB
      Current and future potential roles of the platinum drugs in the treatment of ovarian cancer

      ANNALS OF ONCOLOGY
    7. Vermorken, JB; Zanetta, G; Oliveira, CFD; van der Burg, MEL; Lacave, AJ; Teodorovic, I; Boes, GH; Colombo, N
      Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma ofthe uterine cervix: An EORTC Gynecological Cancer Cooperative Group study

      ANNALS OF ONCOLOGY
    8. Wagenaar, HC; Pecorelli, S; Vergote, I; Curran, D; Wagener, DJT; Kobierska, A; Bolis, G; ten Bokkel-Huinink, W; Lacave, AJ; Madronal, C; Forni, M; de Oliveira, CF; Mangioni, C; Nooij, MA; Goupil, A; Kerbrat, P; Marth, C; Tumolo, S; Herben, MG; Zanaboni, F; Vermorken, JB
      Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced Fallopian tube carcinoma - An EORTC Gynecological Cancer Group Study

      EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
    9. Baay, MFD; Tjalma, WAA; Weyler, J; Goovaerts, G; Buytaert, P; Van Marck, EAE; Lardon, F; Vermorken, JB
      Human papillomavirus infection in the female population of Antwerp, Belgium: prevalence in healthy women, women with premalignant lesions and cervical cancer

      EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
    10. Bos, AME; de Vries, EGE; Dombernovsky, P; Aamdal, S; Uges, DRA; Schrijvers, D; Wanders, J; Roelvink, MWJ; Hanauske, AR; Bortini, S; Capriati, A; Crea, AEG; Vermorken, JB
      Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    11. Tjalma, WA; Weyler, JJ; Bogers, JJ; Pollefliet, C; Baay, M; Goovaerts, GC; Vermorken, JB; van Dam, PA; van Marck, EA; Buytaert, PM
      The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer

      EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY
    12. Van den Brande, J; Panday, VRN; Hoekman, K; Rosing, H; Huijskes, RVHP; Verheijen, RHM; Beijnen, JH; Vermorken, JB
      Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    13. Hanna, MG; Hoover, HC; Vermorken, JB; Harris, JE; Pinedo, HM
      Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise

      VACCINE
    14. Wagenaar, HC; Colombo, N; Vergote, I; Hoctin-Boes, G; Zanetta, G; Pecorelli, S; Lacave, AJ; van Hoesel, Q; Cervantes, A; Bolis, G; Namer, M; Lhomme, C; Guastalla, JP; Nooij, MA; Poveda, A; di Palumbo, VS; Vermorken, JB
      Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: An EORTC Gynaecological Cancer Cooperative Group study

      GYNECOLOGIC ONCOLOGY
    15. van Rijswijk, REN; Vermorken, JB
      Drug therapy for gynaecological cancer in older women

      DRUGS & AGING
    16. Vermorken, JB; Mangioni, C; Pecorelli, S; Van Der Burg, MEL; Van Oosterom, AT; Huinink, WWT; Rotmensz, N; Dalesio, O
      Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP)in disseminated squamous cell carcinoma of the uterine cervix

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    17. Poveda, A; Vermorken, JB
      Untitled - Preface

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    18. Vermorken, JB
      The role of intraperitoneal chemotherapy in epithelial ovarian cancer

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    19. Favalli, G; Vermorken, JB; Vantongelen, K; Renard, J; Van Oosterom, AT; Pecorelli, S
      Quality control in multicentric clinical trials. An experience of the EORTC gynecological cancer cooperative group

      EUROPEAN JOURNAL OF CANCER
    20. Lhomme, C; Vermorken, JB; Mickiewicz, E; Chevalier, B; Alvarez, A; Mendiola, C; Pawinski, A; Lentz, MA; Pecorelli, S
      Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study

      EUROPEAN JOURNAL OF CANCER
    21. Baars, A; Claessen, AME; van den Eertwegh, AJM; Gall, HE; Stam, AGM; Meijer, S; Giaccone, G; Meijer, CJLM; Scheper, RJ; Wagstaff, J; Vermorken, JB; Pinedo, HM
      Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients

      ANNALS OF ONCOLOGY
    22. Vermorken, JB; Kobierska, A; Chevallier, B; Zanaboni, F; Pawinski, A; Bolis, G
      A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin

      ANNALS OF ONCOLOGY
    23. Postma, TJ; Heimans, JJ; Luykx, SA; van Groeningen, CJ; Beenen, LFM; Hoekstra, OS; Taphoorn, MJB; Zonnenberg, BA; Klein, M; Vermorken, JB
      A phase II study of paclitaxel in chemonaive patients with recurrent high-grade glioma

      ANNALS OF ONCOLOGY
    24. Vermorken, JB
      Educational book of the 25th ESMO Congress - Hamburg, Germany, 13-17 October 2000 - Introduction

      ANNALS OF ONCOLOGY
    25. Vermorken, JB
      Optimal treatment for ovarian cancer: taxoids and beyond

      ANNALS OF ONCOLOGY
    26. Mentens, Y; Schrijvers, D; Van den Brande, J; Van Schil, P; Vermorken, JB
      Thoracic wall prosthesis prevents deep invasion by non-small-cell lung cancer

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    27. van Toorn, DW; Nortier, JWR; Rubach, M; de Swart, CAM; Huldij, JC; van Tinteren, H; Vermorken, JB
      Randomized phase II study of FEC day 1+8 and FEC day 1 in patients with advanced breast cancer

      BREAST CANCER RESEARCH AND TREATMENT
    28. Vermorken, JB
      Adjuvant immunotherapy in colorectal cancer

      SEMINARS IN ONCOLOGY
    29. Schrijvers, D; Van den Brande, J; Vermorken, JB
      Supravenous discoloration of the skin due to docetaxel treatment

      BRITISH JOURNAL OF DERMATOLOGY
    30. Pelgrims, J; De Vos, F; Van den Brande, J; Schrijvers, D; Prove, A; Vermorken, JB
      Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature

      BRITISH JOURNAL OF CANCER
    31. Vergote, I; Rustin, GJS; Eisenhauer, EA; Kristensen, GB; Pujade-Lauraine, E; Parmar, MKB; Friedlander, M; Jakobsen, A; Vermorken, JB
      Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    32. Welink, J; Boven, E; Vermorken, JB; Gall, HE; van der Vijgh, WJF
      Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal or liverfunction

      CLINICAL CANCER RESEARCH
    33. Panday, VRN; Huinink, WWT; Vermorken, JB; Rosing, H; Koopman, FJ; Swart, M; Schellens, JHM; Beijnen, JH
      Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion

      PHARMACOLOGICAL RESEARCH
    34. Pecorelli, S; Wagenaar, HC; Vergote, IB; Curran, D; Beex, LVA; Wiltshaw, E; Vermorken, JB
      Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC gynaecological cancer cooperative group study

      EUROPEAN JOURNAL OF CANCER
    35. van Moorsel, CJA; Pinedo, HM; Veerman, G; Vermorken, JB; Postmus, PE; Peters, GJ
      Scheduling of gemcitabine and cisplatin in Lewis Lung tumour bearing mice

      EUROPEAN JOURNAL OF CANCER
    36. Schrijvers, D; Highley, R; De Bruyn, E; Van Oosterom, AT; Vermorken, JB
      Role of red blood cells in pharmacokinetics of chemotherapeutic agents

      ANTI-CANCER DRUGS
    37. van Gijn, R; Huinink, WWT; Rodenhuis, S; Vermorken, JB; van Tellingen, O; Rosing, H; van Warmerdam, LJC; Beijnen, JH
      Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study

      ANTI-CANCER DRUGS
    38. Planting, AST; Catimel, G; de Mulder, PHM; de Graeff, A; Hoppener, F; Verweij, J; Oster, W; Vermorken, JB
      Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer

      ANNALS OF ONCOLOGY
    39. van Moorsel, CJA; Kroep, JR; Pinedo, HM; Veerman, G; Voorn, DA; Postmus, PE; Vermorken, JB; van Groeningen, CJ; van der Vijgh, WJF; Peters, GJ
      Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors

      ANNALS OF ONCOLOGY
    40. Kroep, JR; Peters, GJ; van Moorsel, CJA; Catik, A; Vermorken, JB; Pinedo, HM; van Groeningen, CJ
      Gemcitabine-cisplatin: A schedule finding study

      ANNALS OF ONCOLOGY
    41. Van den Brande, J; Schrijvers, D; Colpaert, C; Vermorken, JB
      Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer

      ANNALS OF ONCOLOGY
    42. Vermorken, JB; Harper, PG; Buyse, M
      The role of anthracyclines in epithelial ovarian cancer

      ANNALS OF ONCOLOGY
    43. Brady, MF; Thigpen, JT; Vermorken, JB; Parmar, MKB
      Randomised trials in ovarian cancer: trial design considerations

      ANNALS OF ONCOLOGY
    44. Piccart, MJ; Stuart, GCE; Cassidy, J; Bertelsen, K; Parmar, MKB; Eisenhauer, EA; Kaye, SB; Trope, C; Swenerton, K; Harper, P; Vermorken, JB
      Intergroup collaboration in ovarian cancer: a giant step forward

      ANNALS OF ONCOLOGY
    45. Berek, JS; Bertelsen, K; du Bois, A; Brady, MF; Carmichael, J; Eisenhauer, EA; Gore, M; Grenman, S; Hamilton, TC; Hansen, SW; Harper, PG; Horvath, G; Kaye, SB; Luck, HJ; Lund, B; McGuire, WP; Neijt, JP; Ozols, RF; Parmar, MKB; Piccart-Gebhart, MJ; van Rijswijk, R; Rosenberg, P; Rustin, GJS; Sessa, C; Thigpen, JT; Trope, C; Tuxen, MK; Vergote, I; Vermorken, JB; Willemse, PHB
      Advanced epithelial ovarian cancer: 1998 consensus statements

      ANNALS OF ONCOLOGY
    46. Greven, K; Petereit, D; Vermorken, JB; Lanciano, R
      Current developments in the treatment of newly diagnosed cervical cancer

      HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    47. Postma, TJ; Hoekman, K; van Riel, JMGH; Heimans, JJ; Vermorken, JB
      Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatinin patients with advanced ovarian cancer

      JOURNAL OF NEURO-ONCOLOGY
    48. Vermorken, JB; Claessen, AMK; van Tinteren, H; Hanna, MG; Pinedo, HM
      Immunotherapy for colon cancer - Reply

      LANCET
    49. Vermorken, JB; Claessen, AME; van Tinteren, H; Gall, HE; Ezinga, R; Meijer, S; Scheper, RJ; Meijer, CJLM; Bloemena, E; Ransom, JH; Hanna, MG; Pinedo, HM
      Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

      LANCET
    50. Vermorken, JB; Huinink, WWT; Kobierska, A; van der Burg, MEL; Forni, M; Piccart, MJ; van der Putten, E
      Phase I study of high-dose epirubicin in platinum-pretreated patients withovarian carcinoma

      ONCOLOGY
    51. Hoekman, K; van der Vijgh, WJF; Vermorken, JB
      Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer

      DRUGS
    52. van Moorsel, CJA; Pinedo, HM; Veerman, G; Bergman, AM; Kuiper, CM; Vermorken, JB; van der Vijgh, WJF; Peters, GJ
      Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

      BRITISH JOURNAL OF CANCER
    53. van Moorsel, CJA; Pinedo, HM; Veerman, G; Guechev, A; Smid, K; Loves, WJP; Vermorken, JB; Postmus, PE; Peters, GJ
      Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines

      BIOCHEMICAL PHARMACOLOGY
    54. ROSING H; HILLEBRAND MJX; JIMENO JM; GOMEZ A; FLORIANO P; FAIRCLOTH G; CAMERON L; HENRAR REC; VERMORKEN JB; BULT A; BEIJNEN JH
      ANALYSIS OF ECTEINASCIDIN-743, A NEW POTENT MARINE-DERIVED ANTICANCERDRUG, IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY IN COMBINATION WITH SOLID-PHASE EXTRACTION

      Journal of chromatography B. Biomedical sciences and applications
    55. PANDAY VRN; VANWARMERDAM LJC; HUIZING MT; HUININK WWT; VERMORKEN JB; GIACCONE G; VEENHOF CHN; SCHELLENS JHM; BEIJNEN JH
      CARBOPLATIN DOSAGE FORMULAS CAN GENERATE INACCURATE PREDICTIONS OF CARBOPLATIN EXPOSURE IN CARBOPLATIN PACLITAXEL COMBINATION REGIMENS/

      Clinical drug investigation
    56. KORST AEC; VANDERSTERRE MLT; GALL HE; FICHTINGERSCHEPMAN AMJ; VERMORKEN JB; VANDERVIJGH WJF
      INFLUENCE OF AMIFOSTINE ON THE PHARMACOKINETICS OF CISPLATIN IN CANCER-PATIENTS

      Clinical cancer research
    57. KORST AEC; VANDERSTERRE MLT; GALL HE; FICHTINGERSCHEPMAN AMJ; VERMORKEN JB; VANDERVIJGH WJF
      INFLUENCE OF AMIFOSTINE ON THE PHARMACOKINETICS OF CISPLATIN IN CANCER-PATIENTS

      Clinical cancer research
    58. ROSING H; HILLEBRAND MJX; JIMENO JM; GOMEZ A; FLORIANO P; FAIRCLOTH G; HENRAR REC; VERMORKEN JB; CVITKOVIC E; BULT A; BEIJNEN JH
      QUANTITATIVE-DETERMINATION OF ECTEINASCIDIN-743 IN HUMAN PLASMA BY MINIATURIZED HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COUPLED WITH ELECTROSPRAY-IONIZATION TANDEM MASS-SPECTROMETRY

      Journal of mass spectrometry
    59. SCHRIJVERS D; PRONK L; HIGHLEY M; BRUNO M; LOCCITONELLI D; DEBRUIJN E; VANOOSTEROM AT; VERWEIJ J; VERMORKEN JB
      SEQUENCE-DEPENDENT PHARMACOKINETICS (PK) OF IFOSFAMIDE (I) COMBINED WITH DOCETAXEL (D)

      European journal of cancer
    60. PELGRIMS J; DEVOS F; SCHRIJVERS D; VANDENBRANDE J; PROVE A; VERMORKEN JB
      METHYLENE-BLUE (MB) IN THE TREATMENT AND PREVENTION OF IFOSFAMIDE (I)ENCEPHALOPATHY

      European journal of cancer
    61. POSTMA TJ; HEIMANS JJ; MULLER MJ; OSSENKOPPELE GJ; VERMORKEN JB; AARONSON NK
      PITFALLS IN GRADING SEVERITY OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY

      Annals of oncology
    62. WAGENER DJT; VERMORKEN JB; HANSEN HH; HOSSFIELD DK
      THE ESMO PROGRAM OF CERTIFICATION AND TRAINING FOR MEDICAL ONCOLOGY

      Annals of oncology
    63. SCHRIJVERS D; VANHERPEN C; KERGER J; JOOSENS E; BRANDELY M; VERMORKEN JB
      PHASE I-II STUDY WITH DOCETAXEL (D), CISPLATIN (C) AND 5-FLUOROURACIL(5-FU) IN PATIENTS WITH LOCALLY ADVANCED INOPERABLE SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

      Annals of oncology
    64. KROEP JR; PETERS GJ; VANMOORSEL CJA; VERMORKEN JB; POSTMUS PE; CATIK A; PINEDO HM; VANGROENINGEN CJ
      GEMCITABINE(GEM)-CISPLATIN (CDDP) - A SCHEDULE FINDING PHASE I II STUDY/

      Annals of oncology
    65. SCHRIJVERS D; PELGRIMS J; VANDENBRANDE J; PROVE A; GOOSSENS H; VERMORKEN JB
      BACTERIAL BLOOD INFECTIONS IN CANCER-PATIENTS

      Annals of oncology
    66. VANMOORSEL CJA; VOORN DA; VEERMAN G; COMIJN EM; SMID K; VANDERVIJGH WJF; POSTMUS PE; VERMORKEN JB; PINEDO HM; PETERS GJ
      MECHANISM(S) OF THE SCHEDULE-DEPENDENT INTERACTION BETWEEN GEMCITABINE (DFDC) AND CISPLATIN (CDDP) IN THE MURINE NONSMALL CELL LUNG (NSCL) TUMOR LEWIS LUNG

      Annals of oncology
    67. VANGIJN R; HUININK WWT; RODENHUIS S; VERMORKEN JB; VANTELLINGEN O; ROSING H; VANWARMERDAM LJC; ALAKL MK; BEIJNEN JH
      PHASE-I AND PHARMACOLOGICAL STUDY WITH THE NOVEL TOPOISOMERASE I II INHIBITOR INTOPLICINE ADMINISTERED AS A 24-HOUR INFUSION/

      Annals of oncology
    68. ROSING H; HILLEBRAND MJX; JIMENO JM; GOMEZ A; FLORIANO P; FAIRCLOTH G; HENRAR REC; VERMORKEN JB; CVITKOVIC E; VILLALONA M; BULT A; BEIJNEN JH
      DETERMINATION OF ECTEINASCIDIN-743 IN HUMAN PLASMA - COMPARISON OF CONVENTIONAL LC UV TO MINIATURIZED LC ELECTROSPRAY-IONIZATION TANDEM MASS-SPECTROMETRY/

      Annals of oncology
    69. KROEP JR; PETERS GJ; VANMOORSEL CJA; CATIK A; VERMORKEN JB; PINEDO HM; VANGROENINGEN CJ
      GEMCITABINE-CISPLATIN COMBINATIONS IN SOLID TUMORS - A SCHEDULE FINDING, PHASE I II CLINICAL-STUDY/

      Annals of oncology
    70. Schrijvers, D; Tai-Apin, C; De Smet, MC; Cornil, P; Vermorken, JB; Bruyneel, P
      Determination of compatibility and stability of drugs used in palliative care

      JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    71. ABE O; ABE R; ENOMOTO K; KIKUCHI K; KOYAMA H; NOMURA Y; SAKAI K; SUGIMACHI K; TOMINAGA T; UCHINO J; YOSHIDA M; BENRAADT J; VANDEVELDE AO; VANDONGEN JA; VERMORKEN JB; GIOKAS G; LISSAIOS B; HARVEY VJ; HOLDAWAY TM; KAY RG; MASON BH; COATES A; FORBES JF; FOCAN C; LOBELLE JP; GATES GD; POWELL J; DURAND M; MAURIAC L; BARTHOLOMEUS S; PICCART MJ; GELMAN RS; HENDERSON IC; SHAPIRO CL; HANCOCK AK; MASOOD MB; PARKER D; PRICE JJ; JACKSON S; RAGAZ J; DELOZIER T; MACELESECH J; HAYBITTLE JL; BERRY D; BROADWATER G; CIRRINCIONE C; MUSS H; NORTON L; BAUM M; HOUGHTON J; RILEY D; DENT DM; GUDGEON CA; HACKING A; GORDON NH; DAVIS HL; ROMESTAING P; LEHINGUE Y; OWEN JR; MEIER P; HOWELL A; RIBEIRO GC; SWINDELL R; ALBANO J; DEOLIVEIRA CF; GERVASIO H; GORDILHO J; CARSTENSEN B; PALSHOF T; JOHANSEN H; KORZENIOWSKI S; SKOLYSZEWSKI J; PORTNOJ SM; ANDERSEN KW; AXELSSON CK; BLICHERTTOFT M; MOURIDSEN HT; OVERGAARD M; ROSE C; CORCORAN N; TRAMPISCH HJ; COMIS RL; DAVIDSON NE; GRAY R; ROBERT N; TORMEY DC; WOOD W; CHETTY U; FORREST P; JACK W; ROSSBACH J; SYLVESTER RJ; VANDEVELDE CJH; CUNNINGHAM MP; BONNETERRE J; FUMOLEAU P; NAMER M; BASTERT G; RAUSCHECKER H; SAUER R; SAUERBREI W; SCHAUER A; SCHUMACHER M; DESCHRYVER A; BELFIGLIO M; MARI E; NICOLUCCI A; SCORPIGLIONE N; YOSEF HMA; MCARDLE CS; SMITH DC; LARA PC; BOCCARDO F; RUBAGOTTI A; ERAZO A; MEDINA JY; IZUO M; MORISHITA Y; BENTLEY A; DORAN Z; FENTIMAN IS; HAYWARD JL; RUBENS RD; KAUFMANN M; JONAT W; SCHEURLEN H; VONFOURNIER D; FOUNTZILAS G; KLAFSTROM P; BLOMQVIST C; CUZICK J; MARGREITER R; CASTIGLIONE M; CAVILLI F; COLLINS J; FORBES J; GELBER RD; GOLDHIRSCH A; LINDTNER J; PRICE KN; RUDENSTAM CM; SENN HJ; BLISS JM; CHILVERS CED; COOMBES RC; MARTY M; BOROVIK R; BRUFMAN G; HAYAT H; ROBINSON E; WIGLER N; PANNUTI F; TAKASHIMA S; YASUTOMI T; SONOO H; YAMASHITA J; OGAWA M; WELVAART K; HUPPERETS PSGJ; BONTE J; TENGRUP I; TENNVALLNITTBY L; MARTIN P; ROMAIN S; INGLE JN; SUMAN VJ; BUZDAR AU; SMITH T; HAKES T; WITTES R; DELAHUERTA R; SAINZ MG; BONADONNA G; DELVECCHIO M; VALAGUSSA P; VERONESI U; DUBOIS JB; BIANCO AR; LIPPMAN ME; PIERCE LJ; SIMON R; STEINBERG SM; MYLES JD; PATER JL; PRITCHARD KI; ANDERSON S; BROWN A; BRYANT J; COSTANTINO J; DIGNAM J; FISHER B; REDMOND C; WIEAND S; WOLMARK N; JACKSON IM; PALMER MK; BENGTSSON NO; LARSSON LG; LYTHGOE JP; KISSIN M; HANNISDAL E; VARHAUG JE; NISSENMEYER R; BLAMEY RW; MITCHELL AK; ROBERTSON JFR; UEO H; MATHE G; MISSET JL; ABUZAHRA HT; CLARKE EA; MCLAUGHLIN JR; CLARK RM; LEVINE M; MORIMOTO K; SAWA K; TAKATSUKA Y; GUNDERSEN S; HAUERJENSEN M; HOST H; CROSSLEY E; HARRIS A; BEIGHTON A; CLARKE M; COLLINS R; DAVIES C; EVANS V; GODWIN J; GREAVES E; HARWOOD C; JACKSON D; JAMES S; LAU E; MEAD G; NAUGHTEN A; PETO R; TOOTH A; RAMBERT P; ASSELAIN B; SALMON RJ; VILCOQ JR; ARRIAGADA R; HILL C; LAPLANCHE A; LE MG; SPIELMANN M; COCCONI G; DIBLASIO B; CATALANO R; CREECH RH; BROCKSCHMIDT J; COOPER MR; ANDRYSEK O; BARKMANOVA J; FALKSON CI; ABRAHAM M; KLIJN JGM; TREURNIETDONKER AD; VANPUTTEN WLJ; EASTON D; POWLES TJ; GAZET JC; SEMIGLAZOV V; DESHPANDE N; DIMARTINO L; DOUGLAS P; LINDTNER A; NOTTER G; BRYANT AJS; EWING GH; KRUSHENKOSLOSKI JL; GEORGE WD; GOULD A; STEWART HJ; STRONER P; MOLLER TR; RYDEN S; CARSTENSEN J; HATSCHEK T; SODERBERG M; CARPENTER JT; ALBAIN K; CROWLEY J; GREEN S; MARTINO S; OSBORNE CK; RAVDIN PM; RUTQVIST LE; WALLGREN A; HOLM LE; THURLIMANN B; BRENNER H; HERCBERGS A; YOSHIMOTO M; DEBOER G; PATERSON AHG; MEAKIN JW; PANZARELLA T; NAJA A; BAHI J; REID M; SPITTLE M; SENANAYAKE F; BERGH J; HOLMBERG L; SEVELDA P; ZIELINSKY CC; GNANT M; JAKESZ R; BUCHANAN RB; CROSS M; DUNN JA; GILLESPIE WM; KELLY K; MORRISON JM; LITTON A; CHLEBOWSKI RT; BEZWODA WR; CAFFIER H
      POLYCHEMOTHERAPY FOR EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS

      Lancet
    72. SCHRIJVERS D; VANDENBRANDE J; VERMORKEN JB
      PULMONARY-EMBOLISM

      The New England journal of medicine
    73. EISENHAUER EA; VERMORKEN JB
      THE TAXOIDS - COMPARATIVE CLINICAL-PHARMACOLOGY AND THERAPEUTIC POTENTIAL

      Drugs
    74. AABO K; ADAMS M; ADNITT P; ALBERTS DS; ATHANAZZIOU A; BARLEY V; BELL DR; BIANCHI U; BOLIS G; BRADY MF; BRODOVSKY HS; BRUCKNER H; BUYSE M; CANETTA R; CHYLAK V; COHEN CJ; COLOMBO N; CONTE PF; CROWTHER D; EDMONSON JH; GENNATAS C; GILBEY E; GORE M; GUTHRIE D; KAYE SB; LAING AH; LANDONI F; LEONARD RC; LEWIS C; LIU PY; MANGIONI C; MARSONI S; MEERPOHL H; OMURA GA; PARMAR MKB; PATER J; PECORELLI S; PRESTI M; SAUERBREI W; SKARLOS DV; SMALLEY RV; SOLOMON HJ; STEWART LA; STURGEON JFG; TATTERSALL MHN; WHARTON JT; HUININK WWT; TOMIROTTI M; TORRI W; TROPE C; TURBOW MM; VERMORKEN JB; WEBB MJ; WILBUR DW; WILLIAMS CJ; WILTSHAW E; YEAP BY
      CHEMOTHERAPY IN ADVANCED OVARIAN-CANCER - 4 SYSTEMATIC METAANALYSES OF INDIVIDUAL PATIENT DATA FROM 39 RANDOMIZED TRIALS

      British Journal of Cancer
    75. Vermorken, JB
      Is there a standard for induction therapy in ovarian cancer?

      EUROCANCER 98
    76. KORST AEC; VERMORKEN JB; VANDERVIJGH WJF
      HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY USING ELECTROCHEMICAL DETECTION FOR THE COMBINED MEASUREMENT OF AMIFOSTINE, WR-1065 AND THE DISULFIDES IN PLASMA

      Journal of chromatography B. Biomedical sciences and applications
    77. PANDAY VRN; HUIZING MT; HUININK WWT; VERMORKEN JB; BEIJNEN JH
      HYPERSENSITIVITY REACTIONS TO THE TAXANES PACLITAXEL AND DOCETAXEL

      Clinical drug investigation
    78. KORST AEC; VANDERSTERRE MLT; EELTINK CM; FICHTINGERSCHEPMAN AMJ; VERMORKEN JB; VANDERVIJGH WJF
      PHARMACOKINETICS OF CARBOPLATIN WITH AND WITHOUT AMIFOSTINE IN PATIENTS WITH SOLID TUMORS

      Clinical cancer research
    79. MULDER WMC; STERN PL; STUKART MJ; DEWINDT E; BUTZELAAR RMJM; MEIJER S; ADER HJ; CLAESSEN AME; VERMORKEN JB; MEIJER CJLM; WAGSTAFF J; SCHEPER RJ; BLOEMENA E
      LOW INTERCELLULAR-ADHESION MOLECULE-1 AND HIGH 5T4 EXPRESSION ON TUMOR-CELLS CORRELATE WITH REDUCED DISEASE-FREE SURVIVAL IN COLORECTAL-CARCINOMA PATIENTS

      Clinical cancer research
    80. GIACCONE G; LINN SC; WELINK J; CATIMEL G; STIELTJES H; VANDERVIJGH WJF; EELTINK C; VERMORKEN JB; PINEDO HM
      A DOSE-FINDING AND PHARMACOKINETIC STUDY OF REVERSAL OF MULTIDRUG-RESISTANCE WITH SDZ PSC-833 IN COMBINATION WITH DOXORUBICIN IN PATIENTS WITH SOLID TUMORS

      Clinical cancer research
    81. KORST AEC; EELTINK CM; VERMORKEN JB; VANDERVIJGH WJF
      PHARMACOKINETICS OF AMIFOSTINE AND ITS METABOLITES IN PATIENTS

      European journal of cancer
    82. VANDERBURG MEL; BOLIS G; BAKKER PJM; CURRAN D; SAHMOUD T; VERMORKEN JB
      PHASE-II STUDY OF WEEKLY 4'-EPIDOXORUBICIN IN PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE CERVIX - AN EORTC GYNECOLOGICAL CANCER COOPERATIVE GROUP-STUDY

      European journal of cancer
    83. VERMORKEN JB; CLAESSEN A; GALL H; VANHOLTEN A; VANTINTEREN H; MEIJER S; STEFFELAAR H; BRAKENHOFF J; VANBOCHOVE A; SCHEPER R; MEIJER C; HANNA M; PINEDO H
      RANDOMIZED PHASE-III TRIAL OF ACTIVE SPECIFIC IMMUNOTHERAPY (ASI) VERSUS CONTROL IN PATIENTS WITH DUKES B2, B3 OR C COLON-CANCER

      European journal of cancer
    84. BIJVANK E; EELTINK C; VERMORKEN JB
      TAXOL-LIKE PREMEDICATION REDUCES THE TOXICITY OF AMIFOSTINE

      European journal of cancer
    85. VANRIJSWIJK REN; HOEKMAN K; BURGER CW; VERHEIJEN RHM; VERMORKEN JB
      EXPERIENCE WITH INTRAPERITONEAL CISPLATIN AND ETOPOSIDE AND IV SODIUMTHIOSULFATE PROTECTION IN OVARIAN-CANCER PATIENTS WITH EITHER PATHOLOGICALLY COMPLETE RESPONSE OR MINIMAL RESIDUAL DISEASE

      Annals of oncology
    86. HONKOOP AH; VANDERWALL E; FELLER N; SCHUURHUIS GJ; VANDERVIJGH WJF; BOVEN E; VANGROENINGEN CJ; GIACCONE G; HOEKMAN K; VERMORKEN JB; WAGSTAFF J; PINEDO HM
      MULTIPLE CYCLES OF HIGH-DOSE DOXORUBICIN AND CYCLOPHOSPHAMIDE WITH G-CSF MOBILIZED PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT IN PATIENTS WITH METASTATIC BREAST-CANCER

      Annals of oncology
    87. EISENHAUER EA; VERMORKEN JB; VANGLABBEKE M
      PREDICTORS OF RESPONSE TO SUBSEQUENT CHEMOTHERAPY IN PLATINUM PRETREATED OVARIAN-CANCER - A MULTIVARIATE-ANALYSIS OF 704 PATIENTS

      Annals of oncology
    88. SCHRIJVERS D; LEFEBVRE JL; VERMORKEN JB
      ONGOING TRIALS IN PATIENTS WITH HEAD AND NECK-CANCER

      European journal of surgical oncology
    89. HUIZING MT; GIACCONE G; VANWARMERDAM LJC; ROSING H; BAKKER PJM; VERMORKEN JB; POSTMUS PE; VANZANDWIJK N; KOOLEN MGJ; HUININK WWTB; VANDERVIJGH WJF; BIERHORST FJ; LAI A; DALESIO O; PINEDO HM; VEENHOF CHN; BEIJNEN JH
      PHARMACOKINETICS OF PACLITAXEL AND CARBOPLAT DOSE-ESCALATING AND DOSE-SEQUENCING STUDY IN WITH NON-SMALL-CELL LONG CANCER

      Journal of clinical oncology
    90. PANDAY VRN; HUIZING MT; WILLEMSE PHB; DEGRAEFF A; HUININK WWT; VERMORKEN JB; BEIJNEN JH
      HEPATIC-METABOLISM OF PACLITAXEL AND ITS IMPACT IN PATIENTS WITH ALTERED HEPATIC-FUNCTION

      Seminars in oncology
    91. VANMOORSEL CJA; VEERMAN G; BERGMAN AM; GUECHEV A; VERMORKEN JB; POSTMUS PE; PETERS GJ
      COMBINATION CHEMOTHERAPY STUDIES WITH GEMCITABINE

      Seminars in oncology
    92. OZOLS RF; VERMORKEN JB
      CHEMOTHERAPY OF ADVANCED OVARIAN-CANCER - CURRENT STATUS AND FUTURE-DIRECTIONS

      Seminars in oncology
    93. LINN SC; PINEDO HM; VANARKOTTE J; VANDERVALK P; HOEKMAN K; HONKOOP AH; VERMORKEN JB; GIACCONE G
      EXPRESSION OF DRUG-RESISTANCE PROTEINS IN BREAST-CANCER, IN RELATION TO CHEMOTHERAPY

      International journal of cancer
    94. BON GG; VONMENSDORFFPOUILLY S; KENEMANS P; VANKAMP GJ; VERSTRAETEN RA; HILGERS J; MEIJER S; VERMORKEN JB
      CLINICAL AND TECHNICAL EVALUATION OF ACS(TM)BR SERUM ASSAY OF MUC1 GENE-DERIVED GLYCOPROTEIN IN BREAST-CANCER, AND COMPARISON WITH CA-15-3 ASSAYS

      Clinical chemistry
    95. VERMORKEN JB; GUASTALLA JP; HATTY SR; SEITZ DE; TANIS B; MCDANIELS C; CLAVEL MD
      PHASE-I STUDY OF GEMCITABINE USING A ONCE EVERY 2 WEEKS SCHEDULE

      British Journal of Cancer
    96. VERMORKEN JB; HUININK WWT
      CHEMOTHERAPY OF ADVANCED BREAST-CANCER - THE PLACE OF ACTIVE NEW DRUGS

      Breast
    97. HOEKMAN K; TOGNON G; RISSE EKJ; BLOEMSMA CA; VERMORKEN JB
      WELL-DIFFERENTIATED PAPILLARY MESOTHELIOMA OF THE PERITONEUM - A SEPARATE ENTITY

      European journal of cancer
    98. STIGGELBOUT AM; KIEBERT GM; DEHAES JCJM; KEIZER HJ; STOTER G; DEWIT R; VERMORKEN JB; LEER JWH; KIEVIT J
      SURVEILLANCE VERSUS ADJUVANT CHEMOTHERAPY IN STAGE-I NONSEMINOMATOUS TESTICULAR CANCER - A DECISION-ANALYSIS

      European journal of cancer
    99. VERWEIJ J; DEMULDER PHM; DEGRAEFF A; VERMORKEN JB; WILDIERS J; KERGER J; SCHORNAGEL J; COGNETTI F; KIRKPATRICK A; SAHMOUD T; LEFEBVRE JL
      PHASE-II STUDY ON MITOXANTRONE IN ADENOID CYSTIC CARCINOMAS OF THE HEAD AND NECK

      Annals of oncology
    100. HONKOOP AH; HOEKMAN K; WAGSTAFF J; BOVEN E; VANGROENINGEN CJ; GIACCONE G; VERMORKEN JB; PINEDO HM
      DOSE-INTENSIVE CHEMOTHERAPY WITH DOXORUBICIN, CYCLOPHOSPHAMIDE AND GM-CSF FAILS TO IMPROVE SURVIVAL OF METASTATIC BREAST-CANCER PATIENTS

      Annals of oncology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/08/20 alle ore 15:45:18